Seres Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Seres Therapeutics

08/08/2023 14:32

* Seres Therapeutics Inc  MCRB.OQ  reported quarterly
adjusted
earnings of 36 cents​​ per share for the quarter ended in June.
The mean expectation of seven analysts for the quarter was
for earnings of 53 cents per share.
    * Revenue rose 10,300.7% to $126.47 million from a year ago;
analysts expected $125.60 million. 
    * Seres Therapeutics Inc's reported EPS for the quarter was
36
cents​.
    * The mean earnings estimate of analysts had risen by
about 19.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Seres Therapeutics Inc shares had fallen by 3.8% this
quarter and lost 17.7% so far this year.
    * The company reported quarterly net income of $46.55
million.
    * Wall Street's median 12-month price target for Seres
Therapeutics Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      0.53           0.36           Missed
 Mar. 31 2023      -0.55          -0.57          Missed
 Dec. 31 2022      -0.46          -0.54          Missed
 Sep. 30 2022      -0.47          -0.49          Missed